CN100584383C - Pharmaceutical composition with Meclofenoxate hydrochloride capable of preventing hydrolysis - Google Patents
Pharmaceutical composition with Meclofenoxate hydrochloride capable of preventing hydrolysis Download PDFInfo
- Publication number
- CN100584383C CN100584383C CN200610122516A CN200610122516A CN100584383C CN 100584383 C CN100584383 C CN 100584383C CN 200610122516 A CN200610122516 A CN 200610122516A CN 200610122516 A CN200610122516 A CN 200610122516A CN 100584383 C CN100584383 C CN 100584383C
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- stabilizing agent
- meclofenoxate
- meclofenoxate hydrochloride
- lubricant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000007062 hydrolysis Effects 0.000 title claims abstract description 17
- 238000006460 hydrolysis reaction Methods 0.000 title claims abstract description 17
- XZTYGFHCIAKPGJ-UHFFFAOYSA-N Meclofenoxate Chemical compound CN(C)CCOC(=O)COC1=CC=C(Cl)C=C1 XZTYGFHCIAKPGJ-UHFFFAOYSA-N 0.000 title claims description 53
- 229960001637 meclofenoxate hydrochloride Drugs 0.000 title claims description 40
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 38
- 239000003381 stabilizer Substances 0.000 claims abstract description 22
- 239000000314 lubricant Substances 0.000 claims abstract description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 42
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 18
- 229920000881 Modified starch Polymers 0.000 claims description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 15
- 239000000741 silica gel Substances 0.000 claims description 15
- 229910002027 silica gel Inorganic materials 0.000 claims description 15
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 13
- 229960003442 meclofenoxate Drugs 0.000 claims description 13
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 13
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 13
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 13
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 230000002378 acidificating effect Effects 0.000 claims description 4
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 claims description 3
- 229910000020 calcium bicarbonate Inorganic materials 0.000 claims description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical group O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 150000007524 organic acids Chemical group 0.000 claims description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 10
- 239000002253 acid Substances 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 abstract description 4
- 239000000843 powder Substances 0.000 abstract description 4
- 229940087458 alcaine Drugs 0.000 abstract 2
- KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 abstract 1
- -1 alcaine methyl chloroformate compound Chemical class 0.000 abstract 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 7
- 239000002775 capsule Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 4
- 238000007907 direct compression Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229960004526 piracetam Drugs 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- FZIPCQLKPTZZIM-UHFFFAOYSA-N 2-oxidanylpropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O FZIPCQLKPTZZIM-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000005030 aluminium foil Substances 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to an alcaine methyl chloroformate compound which can avoid hydrolysis. Wherein, said compound comprises active component alcaine methyl chloroformate, findings, lubricant and stabilizer, while the stabilizer can keep the compound at weak acid. And the invention uses full powder compress method to avoid hydrolysis problem.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition with Meclofenoxate hydrochloride that prevents hydrolysis, more particularly, the present invention relates to a kind of pharmaceutical composition with Meclofenoxate hydrochloride that prevents hydrolysis stabilizer.
Background technology
Meclofenoxate hydrochloride (Meclofenoxate, have another name called meclofenoxane) can promote corticocerebral brain cell metabolism, increase is to the effect of carbohydrate, improve the irritability of neurocyte, clinical application range is gradually wide in recent years, and anoxia neonatorum, blunt, the enuresis, various dull and stupor are had significant curative effect.
For example, Chinese patent application 03131072 discloses a kind of preparation technology and prescription that contains the compound preparation of meclofenoxate and piracetam.This compound preparation has effects such as disturbance of consciousness that a variety of causes such as improving alzheimer disease patient, cerebral infarction, cerebral trauma causes and hypomnesis, mechanism of action is clear and definite, it comprises piracetam and meclofenoxate and pharmaceutic adjuvant, can be made into injection freeze-dried powder, injection, injection powder pin, tablet, capsule, granule, route of administration is intravenously administrable, oral and perfusion etc.
But meclofenoxate hydrochloride is hydrolysis or deliquescence very easily.This easy hygroscopy is the one of the main reasons that influences its tablet quality for a long time.
Therefore, be necessary to provide a kind of meclofenoxate hydrochloride prescription that is difficult for deliquescence or hydrolysis, the deliquescence problem during with solution meclofenoxate hydrochloride sheet commercial production in the tabletting process, and the decomposition of reduction meclofenoxate hydrochloride.
Summary of the invention
The purpose of this invention is to provide a kind of pharmaceutical composition with Meclofenoxate hydrochloride and preparation thereof that prevents hydrolysis.
For realizing above-mentioned goal of the invention, the invention provides a kind of pharmaceutical composition with Meclofenoxate hydrochloride that prevents hydrolysis, this pharmaceutical composition comprises active ingredient hydrochloric acid meclofenoxate, pharmaceutic adjuvant and lubricant, and, this pharmaceutical composition also further contains stabilizing agent, and this stabilizing agent is to make pharmaceutical composition keep weakly acidic material.
In the aforementioned pharmaceutical compositions, the weight percentage of each component is:
Meclofenoxate hydrochloride 40-85%
Adjuvant 5-55%
Lubricant 2-18%
Stabilizing agent 0.5-8%
Preferably, the weight percentage of each component is in the pharmaceutical composition of the present invention:
Meclofenoxate hydrochloride 50-80%
Adjuvant 10-45%
Lubricant 3-15%
Stabilizing agent 1-6%
More preferably, the weight percentage of each component is in the pharmaceutical composition of the present invention:
Meclofenoxate hydrochloride 60-80%
Adjuvant 10-35%
Lubricant 5-10%
Stabilizing agent 1-5%
In pharmaceutical composition of the present invention, preferred stabilizing agent is citric acid, malic acid and/or calcium bicarbonate.In addition, except acidic materials, also can contain other material in the stabilizing agent, as sodium chloride.Preferred stabilizing agent is citric acid (or citric acid).
Why the present invention adopts the stabilizing agent of acidic materials as meclofenoxate hydrochloride, be because: meclofenoxate hydrochloride be hydrolyzed to first order reaction, under 20 ℃ temperature, when pH=2.35, its rate constant is 0.183 * 10
-4, when pH=7.54 then its rate constant up to 134.0 * 10
-4Corresponding, under 20 ℃ temperature, decompose the required time of 10% meclofenoxate hydrochloride when pH=2.35 and during pH=7.54 to be respectively 94.7h and 7.7min, this proves absolutely that meclofenoxate hydrochloride is comparatively stable under faintly acid environment.When pH increased, the meclofenoxate hydrochloride hydrolysis was accelerated; Generally when pH 5 when above, meclofenoxate hydrochloride promptly very easily is hydrolyzed.Thereby when producing meclofenoxate hydrochloride pharmaceutical preparation, the acid or alkali environment of control pharmaceutical composition has bigger influence to its stability.
In addition, if add an amount of citric acid in the pharmaceutical composition, it can keep the local environment faintly acid on the one hand, helps preventing the hydrochloric acid first: the fragrant ester of chlorine is hydrolyzed; On the other hand, citric acid also plays the effect of trace meter chelating agen, can delay the generation of metal catalytic hydrolysis.So for the present invention, preferred stabilizing agent is to have multi-functional organic acid, for example has the organic acid of two or more carboxyls.
In the pharmaceutical composition of the present invention, should select for use and draw moist little pharmaceutic adjuvant, with the stability of further assurance medicine at duration of storage.Lactose is a kind of adjuvant that is usually used in the medicine, but its hygroscopicity is big, during direct compression, and stable unfavorable to meclofenoxate hydrochloride, also unfavorable to the storage of the tablet after the preparation; Though pregelatinized Starch has certain moisture, separately tabletting is unfavorable for the stable of meclofenoxate hydrochloride, and pregelatinized Starch compressibility and flowability are all good, when itself and microcrystalline Cellulose share, can reach even more ideal effect.So in the pharmaceutical composition of the present invention, used pharmaceutic adjuvant is microcrystalline Cellulose and/or pregelatinized Starch, preferred pharmaceutic adjuvant is the combination of microcrystalline Cellulose and pregelatinized Starch.
In pharmaceutical composition of the present invention, though lubricant can be Pulvis Talci, magnesium stearate, micropowder silica gel or its mixture, but preferred micropowder silica gel, because micropowder silica gel has higher moisture content absorptive capacity, usually be used as the desiccant of chemical drugs and pharmaceuticals, in case atmospheric moisture, and micropowder silica gel can be made the cleanser of the local moisture content of tablet, in order to absorb the free water in the tablet micropore, to reduce the interaction of moisture content and drug molecule, meclofenoxate hydrochloride has also been played certain Stabilization.On the contrary, magnesium stearate is then relatively poor, and it may contain free metal ion, and catalytic action is played in the hydrolysis of meclofenoxate hydrochloride.So the present invention preferably adopts micropowder silica gel, not only can play the effect of lubricant, can also play function of stabilizer.
Pharmaceutical composition of the present invention can be made dosage forms such as tablet, capsule.If adopt the direct compression of full-powder method, can reduce the dry run of moisture granulation, thereby reduce the probability of meclofenoxate hydrochloride hydrolysis in process of production.
In addition, aspect the packing of preparation, packaging material also are the important steps that improves stability of drug products, bread layer of aluminum paper tinsel outside, and sealing separately with air-isolation better, is played the effect that prevents hydrolysis.Experiment finds, finds to select for use that the stability of meclofenoxate hydrochloride improves greatly behind the aluminium foil.
Compositions of the present invention and preparation can prevent the hydrolysis of meclofenoxate hydrochloride effectively.
Below, explain the present invention in conjunction with specific embodiments.But these specific embodiment are not to be limitation of the invention.On basis of the present invention, those of ordinary skill in the art can make corresponding improvement or change without creative work fully, but these improvement or change are still in protection scope of the present invention.
The specific embodiment
In the following experiment, employed experimental raw comprises: meclofenoxate hydrochloride, micropowder silica gel, microcrystalline Cellulose, pregelatinized Starch, citric acid (citric acid), Pulvis Talci etc.; Employed equipment mainly comprises the mechanical, electrical hot constant incubator of 19 stampings etc.
Embodiment 1
Prepare every preparation that contains active ingredient hydrochloric acid meclofenoxate 100mg, the prescription of the pharmaceutical composition of its use is:
Meclofenoxate hydrochloride 200g
Microcrystalline Cellulose 10g
Pregelatinized Starch 40g
Porous silica gel 20g
Citric acid 5g
Concrete preparation method:
Capsule is filled: with above-mentioned meclofenoxate hydrochloride, microcrystalline Cellulose, pregelatinized Starch, porous silica gel, citric acid mix homogeneously, adopt direct compression process, and mixing, filled capsules makes the hydrochloric meclofenoxate 100mg of every capsules.
Embodiment 2
Prepare every preparation that contains active ingredient hydrochloric acid meclofenoxate 20mg by embodiment 1 identical method, the prescription of the pharmaceutical composition of its use is:
Meclofenoxate hydrochloride 100g
Microcrystalline Cellulose 20g
Pregelatinized Starch 40g
Porous silica gel 20g
Citric acid 5g
Embodiment 3
Prepare every preparation that contains active ingredient hydrochloric acid meclofenoxate 20mg by embodiment 1 identical method, the prescription of the pharmaceutical composition of its use is:
Meclofenoxate hydrochloride 100g
Microcrystalline Cellulose 5g
Pregelatinized Starch 5g
Porous silica gel 10g
Citric acid 5g
Embodiment 4
Prepare every preparation that contains active ingredient hydrochloric acid meclofenoxate 20mg by embodiment 1 identical method, the prescription of the pharmaceutical composition of its use is:
Meclofenoxate hydrochloride 100g
Pregelatinized Starch 5g
Porous silica gel 20g
Citric acid 0.5g
Embodiment 5
Prepare every preparation that contains active ingredient hydrochloric acid meclofenoxate 20mg by embodiment 1 identical method, the prescription of the pharmaceutical composition of its use is:
Meclofenoxate hydrochloride 100g
Microcrystalline Cellulose 20g
Pregelatinized Starch 10g
Porous silica gel 5g
Citric acid 3g
Embodiment 6
Prepare every preparation that contains active ingredient hydrochloric acid meclofenoxate 20mg by embodiment 1 identical method, the prescription of the pharmaceutical composition of its use is:
Meclofenoxate hydrochloride 100g
Microcrystalline Cellulose 10g
Pregelatinized Starch 10g
Porous silica gel 10g
Citric acid 5g
Claims (8)
1, a kind of pharmaceutical composition with Meclofenoxate hydrochloride that prevents hydrolysis, this pharmaceutical composition is made up of active ingredient hydrochloric acid meclofenoxate, stabilizing agent, lubricant and pharmaceutic adjuvant, it is characterized in that, described stabilizing agent is organic acid and/or the calcium bicarbonate that has two or more carboxyls, and this stabilizing agent can make described pharmaceutical composition keep weakly acidic material; Described lubricant is Pulvis Talci, magnesium stearate, micropowder silica gel or its mixture; Described pharmaceutic adjuvant is microcrystalline Cellulose and/or pregelatinized Starch; Wherein, in the described pharmaceutical composition, the weight percentage of each component is:
Meclofenoxate hydrochloride 40-85%
Pharmaceutic adjuvant 5-55%
Lubricant 2-18%
Stabilizing agent 0.5-8%.
2, pharmaceutical composition as claimed in claim 1 is characterized in that, described stabilizing agent is citric acid, malic acid and/or calcium bicarbonate.
3, pharmaceutical composition as claimed in claim 2 is characterized in that, described stabilizing agent is a citric acid.
4, pharmaceutical composition as claimed in claim 1 is characterized in that, in the described pharmaceutical composition, the weight percentage of each component is:
Meclofenoxate hydrochloride 50-80%
Pharmaceutic adjuvant 10-45%
Lubricant 3-15%
Stabilizing agent 1-6%.
6, pharmaceutical composition as claimed in claim 5 is characterized in that, in the described pharmaceutical composition, the weight percentage of each component is:
Meclofenoxate hydrochloride 60-80%
Pharmaceutic adjuvant 10-35%
Lubricant 5-10%
Stabilizing agent 1-5%.
As the described pharmaceutical composition of one of claim 1-5, it is characterized in that 6, described pharmaceutic adjuvant is microcrystalline Cellulose and/or pregelatinized Starch.
As the described pharmaceutical composition of one of claim 1-5, it is characterized in that 7, described lubricant is micropowder silica gel.
As the described pharmaceutical composition of one of claim 1-5, it is characterized in that 8, described pharmaceutic adjuvant is the compositions of microcrystalline Cellulose and pregelatinized Starch.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610122516A CN100584383C (en) | 2006-09-29 | 2006-09-29 | Pharmaceutical composition with Meclofenoxate hydrochloride capable of preventing hydrolysis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610122516A CN100584383C (en) | 2006-09-29 | 2006-09-29 | Pharmaceutical composition with Meclofenoxate hydrochloride capable of preventing hydrolysis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1951501A CN1951501A (en) | 2007-04-25 |
| CN100584383C true CN100584383C (en) | 2010-01-27 |
Family
ID=38058181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200610122516A Active CN100584383C (en) | 2006-09-29 | 2006-09-29 | Pharmaceutical composition with Meclofenoxate hydrochloride capable of preventing hydrolysis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100584383C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103214382B (en) * | 2013-04-24 | 2014-04-02 | 四川省惠达药业有限公司 | Meclofenoxate hydrochloride compound and pharmaceutical composition thereof |
-
2006
- 2006-09-29 CN CN200610122516A patent/CN100584383C/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN1951501A (en) | 2007-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102196811B (en) | Stable tablet containing 4,5-epoxymorphinan derivative | |
| EP2815752B1 (en) | Oral pharmaceutical composition | |
| CA2861480C (en) | Oral composition comprising .alpha.,.alpha.,.alpha.-trifluorothymidine (ftd), 5-chloro-6-(2-iminopyrrolidine-1-yl)methyl-2,4(1h,3h)-pyrimidine dione hydrochloride (tpi) | |
| RU2008107580A (en) | COMPOSITIONS CONTAINING BASEDOXIFEN ACETATE | |
| JP6195424B2 (en) | Solid pharmaceutical preparations containing levothyroxine | |
| JP5201819B2 (en) | Solid composition | |
| EP3087989B1 (en) | Solid preparations comprising tofogliflozin and method for producing the same | |
| JP2017002045A (en) | Orally disintegrating tablet | |
| CN100584383C (en) | Pharmaceutical composition with Meclofenoxate hydrochloride capable of preventing hydrolysis | |
| CA3108993C (en) | Pharmaceutical composition for oral administration | |
| JP6114573B2 (en) | Solid formulation containing loxoprofen sodium and antacid | |
| JP5113476B2 (en) | Temocapril hydrochloride tablets with excellent storage stability | |
| CN112121021B (en) | Pharmaceutical composition containing linaclotide and preparation method thereof | |
| JP2018083763A (en) | Intraoral foaming formulation and production method thereof | |
| WO2014091263A1 (en) | Telmisartan containing pharmaceutical composition | |
| JP6461496B2 (en) | Antipyretic analgesic | |
| CN1660107A (en) | Solid preparation taken through oral cavity of compound MEthoxyphEnaminE and preparation method | |
| JP2006117694A (en) | Additive for preparation | |
| WO2019230017A1 (en) | Tablet and production method therefor | |
| CN105310989A (en) | Prasugrel oxalate tablet and preparation method of same | |
| CA2474014A1 (en) | Pharmaceutical composition comprising 2,2-dichloro-12-(4-chlorophenyl)-dodecanoic acid | |
| JP2019210276A (en) | Tablet and method for producing the same | |
| JP2019019147A (en) | Analgestic-antipyretic pharmaceutical | |
| JP2019137651A (en) | Pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: XIANQIANG PHARMACEUTICAL CO., LTD., GUANGDONG Free format text: FORMER OWNER: YOUYI MEDICAL TECH DEVELOPMENT CO., LTD., GUANGDONG Effective date: 20120331 Free format text: FORMER OWNER: XIANQIANG PHARMACEUTICAL CO., LTD., GUANGDONG Effective date: 20120331 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 510405 GUANGZHOU, GUANGDONG PROVINCE TO: 510990 GUANGZHOU, GUANGDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20120331 Address after: 510990 Industrial Road, Conghua Economic Development Zone, Guangzhou, Guangdong, Guangdong Patentee after: Xianqiang Pharmaceutical Co., Ltd., Guangdong Address before: 703 room 510405, Jinmao Tower, 17 Guangzhou Airport Road, Guangdong, Guangzhou, China Co-patentee before: Xianqiang Pharmaceutical Co., Ltd., Guangdong Patentee before: Youyi Medical Tech Development Co., Ltd., Guangdong |
|
| C56 | Change in the name or address of the patentee |
Owner name: GUANGDONG XIANQIANG PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: XIANQIANG PHARMACEUTICAL CO., LTD., GUANGDONG |
|
| CP03 | Change of name, title or address |
Address after: 510990 No. 6, Industrial Avenue, Conghua Economic Development Zone, Guangdong, Guangzhou Patentee after: Guangdong Xianqiang Pharmaceutical Co., Ltd. Address before: 510990 Industrial Road, Conghua Economic Development Zone, Guangzhou, Guangdong, Guangdong Patentee before: Xianqiang Pharmaceutical Co., Ltd., Guangdong |
|
| C56 | Change in the name or address of the patentee |
Owner name: XIANQIANG PHARMACEUTICAL CO., LTD., GUANGDONG Free format text: FORMER NAME: GUANGDONG XIANQIANG PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 510990 No. 6, Industrial Avenue, Conghua Economic Development Zone, Guangdong, Guangzhou Patentee after: Xianqiang Pharmaceutical Co., Ltd., Guangdong Address before: 510990 No. 6, Industrial Avenue, Conghua Economic Development Zone, Guangdong, Guangzhou Patentee before: Guangdong Xianqiang Pharmaceutical Co., Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20201118 Address after: No.6, Gongye Avenue, Conghua Economic Development Zone, Guangzhou City, Guangdong Province Patentee after: GUANGDONG XIANQIANG PHARMACEUTICAL Co.,Ltd. Patentee after: Guangdong Zhongsheng Pharmaceutical Co.,Ltd. Patentee after: GUANGDONG HUANAN PHARMACY Ltd. Address before: 510990 No. 6, Industrial Avenue, Conghua Economic Development Zone, Guangdong, Guangzhou Patentee before: GUANGDONG XIANQIANG PHARMACEUTICAL Co.,Ltd. |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Huang Caifeng Document name: Notice of conformity |